Three independent discounted-cash-flow-style models value Biogen Inc. every trading day. 2 of 3 currently price BIIB above its market price.
| Free Cash Flow model | $358.07 |
| Excess Profit model | $237.86 |
| Residual Earnings model | $92.48 |
| Dividend Discount model | — |
| Piotroski F-Score | 5 / 9 |
| Return on invested capital | +7.9% |
| Net debt / EBITDA | 1.2× |
| Gross margin | +75.7% |
| Revenue CAGR | -0.9% |
| Cash conversion | 1.7× |
| Dividend yield | — |
| Buyback yield | -0.7% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open BIIB in StockKitty